Related references
Note: Only part of the references are listed.Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
Roarke A. Kamber et al.
NATURE (2021)
Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment
Traian Sulea et al.
MABS (2020)
Role of CD98 in liver disease
Brandon S. B. Canup et al.
ANNALS OF HEPATOLOGY (2020)
UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
Claudia Arndt et al.
ONCOIMMUNOLOGY (2020)
Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex
Renhong Yan et al.
NATURE (2019)
Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy
Jeffrey C. Kang et al.
NATURE BIOTECHNOLOGY (2019)
Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc
Yongchan Lee et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2019)
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston et al.
NATURE (2019)
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils
Louise W. Treffers et al.
FRONTIERS IN IMMUNOLOGY (2019)
Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer
Bo Xiao et al.
ACS NANO (2018)
A potent human neutralizing antibody Fc-dependently reduces established HBV infections
Dan Li et al.
ELIFE (2017)
Tumour acidosis: from the passenger to the driver's seat
Cyril Corbet et al.
NATURE REVIEWS CANCER (2017)
CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia
Jeevisha Bajaj et al.
CANCER CELL (2016)
Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth
Yann Cormerais et al.
CANCER RESEARCH (2016)
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Y. Joy Yu Zuchero et al.
NEURON (2016)
Integrative discovery of CD98 as a melanoma biomarker
Nicholas Theodosakis et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression
Isaac S. Harris et al.
CANCER CELL (2015)
Antitumor activity of an anti-CD98 antibody
Gregory M. Hayes et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Falk Nimmerjahn et al.
TRENDS IN IMMUNOLOGY (2015)
CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma
Miroru Toyoda et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer
M. Toyoda et al.
BRITISH JOURNAL OF CANCER (2014)
Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics
Linn Fagerberg et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Structural bases for the interaction and stabilization of the human amino acid transporter LAT2 with its ancillary protein 4F2hc
Albert Rosell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
Luika A. Timmerman et al.
CANCER CELL (2013)
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Xuanming Yang et al.
MOLECULAR THERAPY (2013)
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies
Ursula J. E. Seidel et al.
FRONTIERS IN IMMUNOLOGY (2013)
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer
K. Kaira et al.
BRITISH JOURNAL OF CANCER (2012)
Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis
Mio Furuya et al.
CANCER SCIENCE (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson et al.
CANCER CELL (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases
Ian F. Robey et al.
CANCER RESEARCH (2009)
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Paul Nicklin et al.
CELL (2009)
CD98hc facilitates B cell proliferation and adaptive humoral immunity
Joseph Cantor et al.
NATURE IMMUNOLOGY (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2008)
The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane
Joana Fort et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
CD98hc (SLC3A2) mediates integrin signaling
CC Feral et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
The targeted disruption of the CD98 gene results in embryonic lethality
H Tsumura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching
CA Sarkar et al.
NATURE BIOTECHNOLOGY (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)